References
- Lieberman JA. Prediction of outcome in first-episode schizophrenia. J Clin Psychiatry 1993; 54(Suppl 3): 13–7
- Meltzer HY. Treatment of the neuroleptic-nonresponsive schizophrenic patient. Schizophr Bull 1992; 18(3): 515–42
- Fenton WS, McGlashan TH. Sustained remission in drug-free schizophrenic patients. Am J Psychiatry 1987; 144(10): 1306–9
- Wyatt RJ. Neuroleptics and the natural course of schizophrenia. Schizophr Bull 1991; 17(2): 325–51
- Van Putten T, Marder SR, Wirshing WC, et al. Neuroleptic plasma levels. Schizophr Bull 1991; 17(2): 197–216
- Van Putten T, Maider SR, Mintz J. A controlled dose comparison of haloperidol in newly admitted schizophrenic patients. Arch Gen Psychiatry 1990; 47(8): 754–8
- Rifkin A, Doddi S, Karajgi B, et al. Dosage of haloperidol for schizophrenia. Arch Gen Psychiatry 1991; 48(2): 166–70
- Schooler NR. Maintenance medication for schizophrenia; strategies for dose reduction. Schizophr Bull 1991; 17 (2): 311–24 [Erratum, Schizophr Bull 1991; 17(3): 366]
- Kaplan HI, Sadock BJ, Grebb JA. Kaplan and Sadocks synopsis of psychiatry. 7th ed. Baltimore: Williams & Wilkins, 1994: 958–9
- Davis JM, Kane JM, Marder SR, et al. Dose response of prophylactic antipsychotics. J Clin Psychiatry 1993; 54(Suppl 3): 24–30
- Marder SR, Van Putten T, Mintz J, et al. Low- and conventional-dose maintenance therapy with fluphenazine decanoate: two-year outcome. Arch Gen Psychiatry 1987: 44(6): 518–21
- Christison GW, Kirch DG, Wyatt RJ. When symptoms persist: choosing among alternative somatic treatments for schizophrenia. Schizophr Bull 1991; 17(2): 217–45
- Carman JS, Bigelow LB, Wyatt RJ. Lithium combined with neuroleptics in chronic schizophrenic and schizoaffective patients. J Clin Psychiatry 1981; 42(3): 124–8
- Wolkowitz OM, Breier A, Doran A, et al. Alprazolam augmentation of the antipsychotic effects of fluphenazine in schizophrenic patients: preliminary results. Arch Gen Psychiatry 1988; 45(7): 664–71
- Okuma T, Yamashita I, Takahashi R, et al. A double-blind study of adjunctive carbamazepine versus placebo on excited states of schizophrenic and schizoaffective disorders. Acta Psychiatr Scand 1989; 80(3): 250–9
- Rifkin A. Pharmacologic strategies in the treatment of schizophrenia. Psychiatr Clin North Am 1993; 16(2): 351–63
- Lindströ m LH. The effect of long-term treatment with clozapine in schizophrenia: a retrospective study in 96 patients treated with clozapine for up to 13 years. Acta Psychiatr Scand 1988; 77(5): 524–9
- Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45(9): 789–96
- Leon CA. Therapeutic effects of clozapine: a 4-year follow-up of a controlled clinical trial. Acta Psychiatr Scand 1979; 59(5): 471–80
- Safferman A, Lieberman JA, Kane JM, et al. Update on the clinical efficacy and side effects of clozapine. Schizophr Bull 1991; 17(2): 247–61
- Meltzer HY. The mechanism of action of novel antipsychotic drugs. Schizophr Bull 1991; 17(2): 263–87
- Krupp P, Barnes P. Leponex-associated granulocytopenia: a review of the situation. Psychopharmacology (Beri) 1989; 99(Suppl): SI 18–21
- Gerlach J. New antipsychotics: classification, efficacy, and adverse effects. Schizophr Bull 1991; 17(2): 289–309
- Chouinard G, Jones B, Remington G, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993; 13 (1): 25–40 [Erratum, J Clin Psychopharmacol 1993; 13(2): 149]
- Claus A, Bollen J, De Cuyper H, et al. Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study. Acta Psychiatr Scand 1992; 85(4): 295–305